Ziconotide acetate - Generic Drug Details

What are the generic drug sources for ziconotide acetate and what is the scope of freedom to operate?

Ziconotide acetate is the generic ingredient in one branded drug marketed by Tersera and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ziconotide acetate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
What excipients (inactive ingredients) are in ziconotide acetate?	ziconotide acetate excipients list
DailyMed Link:	ziconotide acetate at DailyMed

Pharmacology for ziconotide acetate

Drug Class	N-type Calcium Channel Antagonist
Mechanism of Action	N-Calcium Channel Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ziconotide acetate

N02BG	Other analgesics and antipyretics
N02B	OTHER ANALGESICS AND ANTIPYRETICS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for ziconotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tersera	PRIALT	ziconotide acetate	INJECTABLE;INTRATHECAL	021060-002	Dec 28, 2004		RX	Yes	Yes
Tersera	PRIALT	ziconotide acetate	INJECTABLE;INTRATHECAL	021060-004	Dec 28, 2004		RX	Yes	Yes
Tersera	PRIALT	ziconotide acetate	INJECTABLE;INTRATHECAL	021060-003	Dec 28, 2004		DISCN	No	No

Expired US Patents for ziconotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tersera	PRIALT	ziconotide acetate	INJECTABLE;INTRATHECAL	021060-001	Dec 28, 2004
Tersera	PRIALT	ziconotide acetate	INJECTABLE;INTRATHECAL	021060-004	Dec 28, 2004
Tersera	PRIALT	ziconotide acetate	INJECTABLE;INTRATHECAL	021060-003	Dec 28, 2004

Ziconotide acetate Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Ziconotide Acetate?

Ziconotide acetate is a synthetic peptide drug used for severe chronic pain management, particularly in cases resistant to other therapies. Its market niche is highly specialized, with demand driven by clinical efficacy and safety profiles.

Market Size and Growth Factors

The global market for Ziconotide acetate is expected to grow steadily. In 2022, the market was valued at approximately $200 million, with forecasts projecting a Compound Annual Growth Rate (CAGR) of around 8% through 2030[1]. Growth drivers include increasing prevalence of chronic pain conditions, advances in delivery mechanisms, and greater adoption in neurology.

Key Market Segments

• Geography: North America currently leads, accounting for over 50% of sales, driven by high healthcare expenditure and top-tier pain management centers. Europe follows, with growth fueled by expanding neurology departments. Asia-Pacific shows potential due to rising awareness and healthcare infrastructure improvements but remains a nascent market.
• Application: Ziconotide is primarily used for pain due to spinal cord injury or cancer, with a smaller segment for other neuropathic pain conditions.

Competitive Landscape

The drug's main competitors are opioid medications and other intrathecal analgesics, including morphine, baclofen, and newer NMDA antagonists. Ziconotide's advantages include no opioid-related dependence but drawbacks like severe side effects limit use. Its market penetration depends heavily on clinician familiarity and approval status.

How Does the Financial Trajectory Look for Ziconotide Acetate?

Revenue Trends

• Historical Data: Revenue was approximately $180 million in 2021, increasing to $200 million in 2022[1].
• Forecast: By 2030, revenues could surpass $350 million, assuming current growth rates continue, adjusted for patent statuses and emerging competitors.

Pricing and Reimbursement

• The average wholesale price (AWP) per dose varies between $2,000 and $2,500.
• Reimbursement policies in the US cover intrathecal drug administration, but coverage fluctuations influence sales.
• Price stabilization is challenged by biosimilar development and generic competition post-patent expiry.

R&D and Patent Considerations

Currently, Ziconotide is under patent protection until 2030. Patent cliff could lead to generic alternatives that pressure pricing and margins. R&D investments focus on alternative delivery systems and combination therapies to extend market exclusivity.

Investment and R&D Outlook

Pharmaceutical firms are investing in improved administration techniques, such as pump-based delivery systems, and exploring novel indications. This diversification could enhance the drug’s lifecycle and revenue streams.

What Are the Regulatory and Market Entry Barriers?

• Strict regulatory approval processes in key markets influence timeline and costs.
• Competitive introduction of new pain management agents, especially non-invasive options, limits market expansion.
• Patient safety concerns and adverse event profiles impact prescribing trends and reimbursement decisions.

How Do Market Drivers and Barriers Shape the Future?

Supply and demand trends suggest stable growth, contingent on clinical acceptance, regulatory approvals, and technological innovations. Shifts toward personalized pain management could influence market size, favoring drugs like Ziconotide that address specific patient subgroups.

---

Key Takeaways

• Market valuation around $200 million (2022), with a forecast CAGR of 8% until 2030.
• North America dominates demand, with growth driven by rising chronic pain cases.
• Revenues projected to surpass $350 million by 2030, subject to patent expiry effects.
• Competitive landscape centers on opioids and emerging intrathecal therapies.
• R&D efforts aim to improve delivery systems and expand therapeutic applications.

---

FAQs

1. How does Ziconotide differ from opioid pain medications?

Ziconotide acts as an N-type calcium channel blocker, providing pain relief without opioid-related dependence. It is administered intrathecally, reducing systemic side effects common with opioids.

2. What are the main side effects associated with Ziconotide?

Severe adverse effects include neuropsychiatric symptoms such as hallucinations, dizziness, and paralysis. These limit its use to specific cases where benefits outweigh risks.

3. When will patent expiration impact Ziconotide's market?

The patent expires around 2030, after which generics and biosimilars could enter the market, potentially reducing prices and revenue.

4. What markets show future growth potential?

Asia-Pacific and emerging regions where neurology infrastructure expands could see increased adoption of Ziconotide.

5. Are there ongoing R&D activities to extend the lifespan of Ziconotide?

Yes, investments focus on alternative delivery methods, combination therapies, and new indications to extend its commercial viability.

---

References

[1] Market Research Future. "Ziconotide Market Report," 2022.